natgillin/translations-raw huggingface dataset:
Lægemidler, der er forbundet med risiko for blødning: Der er en øget risiko for blødning på grund af mulig additiv virkning.
Medicinal products associated with bleeding risk: There is an increased risk of bleeding due to the potential additive effect.
Clopidogrel og den cirkulerende (inaktive) hovedmetabolit binder reversibelt in vitro til humane plasmaproteiner (henholdsvis 98 % og 94 %).
Clopidogrel and the main circulating (inactive) metabolite bind reversibly in vitro to human plasma proteins (98 % and 94 % respectively).
Yderligere oplysninger om dette lægemiddel er tilgængelig på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu/.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.
Bivirkninger, der opstod enten under de kliniske studier, eller der spontant blev indberettet, er beskrevet i tabellen nedenfor.
Adverse reactions that occurred either during clinical studies or that were spontaneously reported are presented in the table below.
Visse andre lægemidler kan påvirke brugen af Clopidogrel Teva Pharma eller omvendt.
Some other medicines may influence the use of Clopidogrel Teva Pharma or vice versa.
Dato for første markedsføringstilladelse: 21. september 2009 Dato for seneste fornyelse: 8. maj 2014
Date of latest renewal: 8 May 2014
Blodplader er meget små bestanddele i blodet, og de klumper sig sammen, når blodet størkner.
Platelets are very small structures in the blood, which clump together during blood clotting.
Patienter, der tidligere har udviklet en allergisk og/eller hæmatologisk reaktion over for en thienopyridin, kan have en øget risiko for at udvikle den samme eller en anden reaktion over for en anden thienopyridin.
Patients who had developed a previous monitored allergic reaction and/or haematological reaction to one thienopyridine may have an increased risk of developing the same or another reaction to another thienopyridine.
Forebyggelse af aterotrombotiske hændelser
Prevention of atherothrombotic events
Forekomsten af alvorlige tilfælde var ens for clopidogrel og ASA.
The incidence of severe cases was similar for clopidogrel and ASA.
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenien TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Tyskland Pharmachemie B.V., Swensweg 5, 2031 GA Haarlem, Holland
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany Pharmachemie B.V., Swensweg 5, 2031 GA Haarlem, The Netherlands
Hvis du får langvarige blødninger, mens du tager Clopidogrel Teva Pharma Hvis du skærer dig eller kommer til skade, kan det tage lidt længere end normalt, før blødningen stopper.
If you experience prolonged bleeding when taking Clopidogrel Teva Pharma If you cut or injure yourself, it may take slightly longer than usual for bleeding to stop.
Du skal fortsætte med at tage Clopidogrel Teva Pharma, så længe som din læge udskriver det til dig.
You should take Clopidogrel Teva Pharma for as long as your doctor continues to prescribe it.
Hvis du har taget for mange Clopidogrel Teva Pharma Kontakt din læge eller nærmeste skadestue, på grund af den øgede risiko for blødning.
If you take more Clopidogrel Teva Pharma than you should Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding.
Du bør være blevet informeret om, at ”orale antikoagulantia” er mere effektive mod denne sygdom end acetylsalicylsyre eller kombinationen af Clopidogrel Teva Pharma og acetylsalicylsyre.
You should have been told that ‘oral anticoagulants' are more effective than acetylsalicylic acid or the combined use of Clopidogrel Teva Pharma and acetylsalicylic acid for this condition.
De klinisk relevante bivirkninger observeret i CAPRIE-, CURE-, CLARITY-, COMMITog ACTIVE-A-studierne beskrives nedenfor.
The clinically relevant adverse reactions observed in the CAPRIE, CURE, CLARITY, COMMIT and ACTIVE-A studies are discussed below.
Der er gennemført en række andre kliniske studier med clopidogrel og anden samtidig medicinering for at undersøge muligheden for farmakodynamisk og farmakokinetisk interaktion.
Other medicinal products: A number of other clinical studies have been conducted with clopidogrel and other concomitant medicinal products to investigate the potential for pharmacodynamic and pharmacokinetic interactions.
Hvis du bliver gravid, mens du tager Clopidogrel Teva Pharma, skal du omgående kontakte din læge, da det frarådes at tage clopidogrel, mens du er gravid.
If you become pregnant while taking Clopidogrel Teva Pharma, consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant.
Hvis du har glemt en dosis af Clopidogrel Teva Pharma, men kommer i tanke om det i løbet af 12 timer, skal du omgående tage tabletten og dernæst tage den næste tablet til sædvanlig tid.
If you forget to take a dose of Clopidogrel Teva Pharma, but remember within 12 hours of your usual time, take your tablet straightaway and then take your next tablet at the usual time.
Ved at forhindre denne sammenklumpning nedsætter medicinen, der opløser blodpropper, risikoen for, at der dannes blodpropper (en proces, der kaldes trombose).
By preventing this clumping, antiplatelet medicinal products reduce the chances of blood clots forming (a process called thrombosis).
Sikkerheden og effekten af clopidrogrel er blevet evalueret i 5 dobbeltblindede studier, der omfattede mere end 88.000 patienter: CAPRIE-studiet, hvor clopidogrel sammenlignes med ASA, og CURE, CLARITY, COMMIT- og ACTIVE-A-studierne, hvor clopidogrel sammenlignes med placebo, og hvor begge lægemidler gives i kombination med ASA eller anden standardterapi.
The safety and efficacy of clopidogrel have been evaluated in 5 double-blind studies involving over 88,000 patients: the CAPRIE study, a comparison of clopidogrel to ASA, and the CURE, CLARITY, COMMIT and ACTIVE-A studies comparing clopidogrel to placebo, both medicinal products given in combination with ASA and other standard therapy.
EU/1/09/561/001 7 filmovertrukne tabletter EU/1/09/561/002 14 filmovertrukne tabletter EU/1/09/561/003 28 filmovertrukne tabletter EU/1/09/561/004 30 filmovertrukne tabletter EU/1/09/561/005 50 filmovertrukne tabletter EU/1/09/561/006 56 filmovertrukne tabletter EU/1/09/561/007 84 filmovertrukne tabletter EU/1/09/561/008 90 filmovertrukne tabletter EU/1/09/561/009 100 filmovertrukne tabletter EU/1/09/561/010 28x1 filmovertrukne tabletter EU/1/09/561/011 50x1 filmovertrukne tabletter
EU/1/09/561/001 7 film-coated tablets EU/1/09/561/002 14 film-coated tablets EU/1/09/561/003 28 film-coated tablets EU/1/09/561/004 30 film-coated tablets EU/1/09/561/005 50 film-coated tablets EU/1/09/561/006 56 film-coated tablets EU/1/09/561/007 84 film-coated tablets EU/1/09/561/008 90 film-coated tablets EU/1/09/561/009 100 film-coated tablets EU/1/09/561/010 28x1 film-coated tablets EU/1/09/561/011 50x1 film-coated tablets
Din læge bør have udskrevet Clopidogrel Teva Pharma plus acetylsalicylsyre, hvis duikke må tage ”orale antikoagulantia”, og du ikke har en risiko for alvorlig blødning.
Your doctor should have prescribed Clopidogrel Teva Pharma plus acetylsalicylic acid if you cannot take ‘oral anticoagulants' and you do not have a risk of major bleeding
MINDSTEKRAV TIL MÆRKNING PÅ BLISTER ELLER STRIP BLISTERKORT (28x1 filmovertrukne tabletter)
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER (28x1 film-coated tablets)
ACTIVE-A-studiet (N = 7.554) var et multicenter, randomiseret, dobbeltblindt, placebokontrolleret studie, som sammenlignede clopidogrel 75 mg/dag + ASA (N = 3.772) med placebo + ASA (N = 3.782).
The ACTIVE-A study (N=7,554) was a multicenter, randomized, double-blind, placebo-controlled study which compared clopidogrel 75 mg/day + ASA (N=3,772) to placebo + ASA (N=3,782).
CYP2C19*1-allelen svarer til en fuldt funktionel metabolisme, mens CYP2C19*2- og CYP2C19*3allelerne ikke er funktionelle.
The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and CYP2C19*3 alleles are nonfunctional.
In vitro-studier har vist, at den øgede eksponering for repaglinid skyldes hæmning af CYP2C8 ved glukuronidmetabolitten af clopidogrel.
In vitro studies have shown the increase in repaglinide exposure is due to inhibition of CYP2C8 by the glucuronide metabolite of clopidogrel.
Den anbefalede ASA-dosis var 75 til 100 mg/dag.
The recommended dose for ASA was 75 to 100 mg/day.
I CURE var der ikke overrepræsentation af større blødninger med clopidogrel plus ASA inden for 7 dage efter koronar bypassoperation hos patienter, der indstillede behandlingen mere end 5 dage før indgrebet.
In CURE, there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery.
Farmakoterapeutisk klassifikation: Antitrombotiske midler, trombocytfunktionshæmmende midler eksklusive heparin, ATC-kode: B01AC-04.
Pharmacotherapeutic group: Antithrombotic agents, platelet aggregation inhibitors excl. heparin, ATC Code: B01AC-04.
Perforerede enhedsdosisblistere af OPA/Al/PVC-Al indeholdende 28x1 og 50x1 filmovertrukne tabletter.
Perforated unit dose blister of OPA/Al/PVC-Al containing 28x1 and 50x1 film-coated tablets in the box.
Den almindeligste bivirkning, indberettet med Clopidogrel Teva Pharma er blødning.
The most common side effect reported with Clopidogrel Teva Pharma is bleeding.
• Risikostyringsprogram
• Risk Management Plan (RMP)
Advarsler og forsigtighedsregler Hvis nogen af følgende situationer gælder for dig, skal du oplyse det til din læge, før du tager Clopidogrel Teva Pharma:
Warnings and precautions If any of the situations mentioned below apply to you, you should tell your doctor before taking Clopidogrel Teva Pharma:
Hos de patienter, som alene indgik i studiet på grund af et nyligt myokardieinfarkt, lå clopidogrel numerisk lavere, men ikke statistisk forskelligt fra ASA (RRR = 4,0 %, CI: -22,5 til 11,7 [p=0,639]).
In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR =4.0%; CI: -22.5 to 11.7 [p=0.639]).
Undersøgelser i neutrofiltal, fald i trombocyttal * Information relateret til clopidogrel med hyppighed ”ikke kendt”.
Bleeding time prolonged, neutrophil count decreased, platelet count decreased * Information related to clopidogrel with frequency “not known”.
Gastrointestinal og retroperitoneal blødning med dødelig udgang, pancreatitis, colitis (inklusive ulcerøs eller forstoppelse, flatulens lymfocytisk colitis), stomatitis
Gastrointestinal and retroperitoneal haemorrhage with fatal outcome, pancreatitis, colitis (including ulcerative or lymphocytic colitis), stomatitis
Trafik- og arbejdssikkerhed Det er usandsynligt at Clopidogrel Teva Pharma påvirker din evne til at køre eller betjene maskiner.
Driving and using machines Clopidogrel Teva Pharma is unlikely to affect your ability to drive or to use machines.
Clopidogrel Teva Pharma indeholder clopidogrel og tilhører en lægemiddelgruppe, der kaldes blodfortyndende medicin.
Clopidogrel Teva Pharma contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products.
I et dosiseskaleringsstudie med 86 nyfødte eller spædbørn op til 24 måneder med risiko for trombose (PICOLO) blev clopidogrel evalueret ved konsekutive doser på 0,01, 0,1 og 0,2 mg/kg til nyfødte og spædbørn og ved 0,15 mg/kg alene til nyfødte.
In a dose escalation study of 86 neonates or infants up to 24 months of age at risk for thrombosis (PICOLO), clopidogrel was evaluated at consecutive doses of 0.01, 0.1 and 0.2 mg/kg in neonates and infants and 0.15 mg/kg only in neonates.
Derefter er den anbefalede dosis 1 Clopidogrel Teva Pharma-tablet på 75 mg daglig som beskrevet ovenfor.
Then, the recommended dose is one 75 mg tablet of Clopidogrel Teva Pharma per day as described above.
7 filmovertrukne tabletter 14 filmovertrukne tabletter 28 filmovertrukne tabletter 30 filmovertrukne tabletter 50 filmovertrukne tabletter 56 filmovertrukne tabletter 84 filmovertrukne tabletter 90 filmovertrukne tabletter 100 filmovertrukne tabletter 28x1 filmovertrukne tabletter 50x1 filmovertrukne tabletter
7 film-coated tablets 14 film-coated tablets 28 film-coated tablets 30 film-coated tablets 50 film-coated tablets 56 film-coated tablets 84 film-coated tablets 90 film-coated tablets 100 film-coated tablets 28x1 film-coated tablets 50x1 film-coated tablets
PolyvinylalkoholTitandioxid (E171) Rød jernoxid (E172) Gul jernoxid
Polyvinyl alcohol Titanium dioxide (E171) Red iron oxide (E172) Yellow iron oxide (E172) Talc
• hvis du er allergisk over for clopidogrel eller et af de øvrige indholdsstoffer i dette lægemiddel
• If you are allergic to clopidogrel or any of the other ingredients of this medicine (listed in section 6).
• skal du også straks fortælle det til din læge, hvis du udvikler en medicinsk tilstand (trombocytisk trombocytopenisk purpura eller TTP), der giver feber og blå mærker under huden, der kan fremstå som røde små prikker, med eller uden uforklarlig udtalt træthed, forvirring, gulfarvning af huden eller øjnene (gulsot) (se pkt.
• You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 ‘Possible side effects').
Bulløs dermatitis (toksisk epidermal nekrolyse, StevensJohnson syndrom, erythema multiforme), akut generaliseret eksantematøs pustulose (AGEP), angioødem, lægemiddelinduceret overfølsomhedssyndrom, medikamentelt udslæt med eosinofili og systemiske symptomer (DRESS), erytematøst eller eksfoliativt udslæt, urticaria, eksem, lichen planus
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme, acute generalised exanthematous pustulosis (AGEP)), angioedema, drug-induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rash erythematous or exfoliative, urticaria, eczema, lichen planus
En dosis på 0,2 mg/kg opnåede en gennemsnitlig procentvis hæmning på 49,3 % (5 µM ADP-induceret trombocytaggregation), hvilket er sammenligneligt med voksne, der tager clopidogrel 75 mg/dag.
The dose of 0.2 mg/kg achieved the mean percent inhibition of 49.3% (5 µM ADP-induced platelet aggregation) which was comparable to that of adults taking Clopidogrel 75 mg/day.
MINDSTEKRAV TIL MÆRKNING PÅ BLISTER ELLER STRIP BLISTER (7, 14, 28, 30, 50, 56, 84, 90, 100, 50x1 filmovertrukne tabletter)
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER (7, 14, 28, 30, 50, 56, 84, 90, 100, 50x1 film-coated tablets)
Hvis du har haft alvorlige smerter i brystet (hjertekrampe (ustabil angina pectoris) eller hjerteanfald), kan din læge ordinere Clopidogrel Teva Pharma i kombination med acetylsalicylsyre, som er et stof, der indgår i mange typer medicin til smertelindring og febersænkning.
If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed Clopidogrel Teva Pharma in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever.
Som forholdsregel bør amning ophøre under behandling med Clopidogrel Teva Pharma.
As a precautionary measure, breast-feeding should not be continued during treatment with Clopidogrel Teva Pharma.
Glycoprotein IIb/IIIa-hæmmere: Clopidogrel skal anvendes med forsigtighed til patienter, der samtidig behandles med glycoprotein IIb/IIIa-hæmmere (se pkt.
Glycoprotein IIb/IIIa inhibitors: clopidogrel should be used with caution in patients who receive concomitant glycoprotein IIb/IIIa inhibitors (see section 4.4).
Hvis du har haft alvorlige brystsmerter (ustabil angina pectoris eller hjertetilfælde), vil din læge måske indlede behandlingen med at give dig 300 mg Clopidogrel Teva Pharma på en gang (4 tabletter på 75 mg).
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Clopidogrel Teva Pharma (4 tablets of 75 mg) once at the start of treatment.
Der er test tilgængelige til at bestemme en patients CYP2C19-genotype
Tests are available to determine a patient's CYP2C19 genotype.
Hvis du mener, at ovenstående gælder for dig, eller hvis du overhovedet er i tvivl, så rådfør dig med din læge, inden du tager Clopidogrel Teva Pharma.
If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Clopidogrel Teva Pharma.
- tegn på leverproblemer såsom gulfarvning af huden og/eller øjnene (gulsot), uanset om det sker i forbindelse med blødninger, som viser sig under huden som små røde prikker, og/eller forvirring (se pkt.
- signs of liver problems such as yellowing of the skin and/or the eyes (jaundice), whether or not associated with bleeding which appears under the skin as red pinpoint dots and/or confusion (see section 2 ‘Warnings and precautions').
CAPRIE-studiet omfattede 19.185 patienter med aterotrombose manifesteret ved nyligt myokardieinfarkt (<35 dage), nyligt iskæmisk apopleksi (mellem 7 dage og 6 måneder) eller påviste perifere kredsløbsforstyrrelser (PAD).
The CAPRIE study included 19,185 patients with atherothrombosis as manifested by recent myocardial infarction (<35 days), recent ischaemic stroke (between 7 days and 6 months) or established peripheral arterial disease (PAD).
Clopidogrel Teva Pharma tages af voksne for at forebygge dannelse af blodpropper (trombi) i blodårer (arterier), som er blevet stive ved en proces kaldet aterotrombose, hvilket kan føre til f.eks. apopleksi, hjerteanfald og død (aterotrombotiske hændelser).
Clopidogrel Teva Pharma is taken by adults to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death).
• Voksne patienter med akut koronarsyndrom: - akut koronarsyndrom uden elevation af ST-segmentet (ustabil angina eller myokardieinfarkt uden forekomst af Q-takker), herunder patienter, som får indsat stent efter perkutant koronarindgreb, i kombination med acetylsalicylsyre (ASA).
• Adult patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
I CLARITY var der en generel stigning i antallet af blødninger i clopidrogrel plus ASA-gruppen versus placebo plus ASA-gruppen.
In CLARITY, there was an overall increase in bleeding in the clopidogrel plus ASA group vs. the placebo plus ASA group.
De har fået ordineret Clopidogrel Teva Pharma til forebyggelse af blodpropper og nedsættelse af risikoen for disse alvorlige hændelser, fordi: - du lider af åreforkalkning (også kaldet aterosklerose) - og - du tidligere har haft et hjerteanfald, apopleksi eller kredsløbsforstyrrelser i arme eller ben- eller - du har haft en alvorlig form for smerter i brystet, som kaldes hjertekrampe (ustabil angina pectoris) eller hjerteanfald (myokardieinfarkt).
You have been prescribed Clopidogrel Teva Pharma to help prevent blood clots and reduce the risk of these severe events because: - You have a condition of hardening of arteries (also known as atherosclerosis), and - You have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease, or - You have experienced a severe type of chest pain known as ‘unstable angina' or ‘myocardial infarction' (heart attack).
KVALITATIV OG KVANTITATIV SAMMENSÆTNING Hver filmovertrukket tablet indeholder 75 mg clopidogrel (som hydrochlorid).
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 75 mg of clopidogrel (as hydrochloride).
• hvis du har en aktiv blødning såsom et mavesår eller en blødning i hjernen.
• If you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain.
Clopidogrel Teva Pharma indeholder hydrogeneret ricinusolie, der kan give maveproblemer og diarré.
Clopidogrel Teva Pharma contains hydrogenated castor oil This may cause stomach upset or diarrhoea.
Tag ikke Clopidogrel Teva Pharma
Do not take Clopidogrel Teva Pharma
Hver filmovertrukket tablet indeholder 13 mg hydrogeneret ricinusolie.
Each film-coated tablet contains 13 mg of hydrogenated castor oil.
Hvis du er gravid eller ammer har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du spørge din læge eller apotekspersonalet til råds, før du tager Clopidogrel Teva Pharma.
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel Teva Pharma.
Æsker med 7, 14, 28, 30, 50, 56, 84, 90 og 100 filmovertrukne tabletter i blisterpakning eller æsker med 28x1 og 50x1 filmovertrukne tabletter i perforerede enhedsdosisblistere.
Boxes of 7, 14, 28, 30, 50, 56, 84, 90 and 100 film-coated tablets in blisters or boxes of 28x1 and 50x1 film-coated tablets in perforated unit dose blisters are available.
Patienterne fik clopidogrel (75 mg/dag, n=22961) eller placebo (n=22891), i kombination med ASA (162 mg/dag) i 28 dage eller indtil udskrivelse fra hospitalet.
Patients received clopidogrel (75 mg/day, n=22,961) or placebo (n=22,891), in combination with ASA (162 mg/day), for 28 days or until hospital discharge.
Ligesom andre antitrombolytika skal clopidogrel anvendes med forsigtighed til patienter med risiko for tiltagende blødninger pga. traumer, kirurgi eller andre patologiske tilstande samt til patienter, der samtidigt behandles med ASA, heparin, glycoprotein IIb/IIIa-hæmmere eller non-steroide antiinflammatoriske lægemidler (NSAID'er) inklusive cox-2-hæmmere eller selektive serotoningenoptagelseshæmmere (SSRI'er), eller andre lægemidler forbundet med risiko for blødning, såsom pentoxifyllin (se pkt.
As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors, or selective serotonin reuptake inhibitors (SSRIs), or other medicinal products associated with bleeding risk such as pentoxifylline (see section 4.5).
Serumsygdom, anafylaktiske reaktioner, krydsallergiske reationer mellem thienopyridiner (såsom ticlopidin, prasugrel) (se pkt.
Serum sickness, anaphylactoid reactions, cross-reactive drug hypersensitivity among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)*
I en delgruppeanalyse af inklusionsgrupperne (myokardieinfarkt, iskæmisk apopleksi og PAD) syntes udbyttet at være størst (dvs. den opnåede statisk signifikans ved p=0,003) hos patienter, som indgik på grund af PAD (især de patienter, som tidligere også havde haft et myokardieinfarkt) (RRR = 23,7 %, CI: 8,9 til 36,2) og mindst (afveg ikke signifikant fra ASA) hos patienter med apopleksi (RRR = 7,3 %, CI: -5,7 til 18,7 [p=0,258]).
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p=0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to 18.7 [p=0.258]).
Hver filmovertrukket tablet indeholder 75 mg clopidogrel (som hydrochlorid).
Each film-coated tablet contains 75 mg of clopidogrel (as hydrochloride).